匯豐研究:升雅生活服務(3319.HK)目標價至39.8港元 評級“買入”
匯豐環球研究發表報告,重申對雅生活服務(03319.HK)的“買入”評級,目標價由29.7港元大幅上調至39.8港元,併為中資物業管理行業首選,因集團增長強勁,2018年至2021年的盈利年均複合增長率料達38%,而且估值具吸引力,目前相當於今年市盈率20倍。
該行表示,去年中資物管行業估值重評持續,而雅生活為該行覆蓋研究的行業股份中表現最佳,股價自去年起上升150%,但對比行業龍頭如綠城服務(02869.HK)及碧桂園服務(06098.HK)等仍有折讓。另一方面,匯豐研究相信集團可滿足於下次指數審核(2月21日)中納入恆生小型股指數的標準,並有潛在可能獲納入南向通交易。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.